000182306 001__ 182306
000182306 005__ 20240229145715.0
000182306 0247_ $$2doi$$a10.3390/cancers14205128
000182306 0247_ $$2pmid$$apmid:36291912
000182306 0247_ $$2altmetric$$aaltmetric:137663277
000182306 037__ $$aDKFZ-2022-02563
000182306 041__ $$aEnglish
000182306 082__ $$a610
000182306 1001_ $$00000-0002-9419-6790$$aSlavc, Irene$$b0
000182306 245__ $$aImproved Long-Term Survival of Patients with Recurrent Medulloblastoma Treated with a 'MEMMAT-like' Metronomic Antiangiogenic Approach.
000182306 260__ $$aBasel$$bMDPI$$c2022
000182306 3367_ $$2DRIVER$$aarticle
000182306 3367_ $$2DataCite$$aOutput Types/Journal article
000182306 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1667214769_18730
000182306 3367_ $$2BibTeX$$aARTICLE
000182306 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000182306 3367_ $$00$$2EndNote$$aJournal Article
000182306 520__ $$aMedulloblastoma (MB) recurrence is usually incurable despite intensive therapy including high-dose chemotherapy. An evolving alternative approach to conventional chemotherapy aims at interfering with tumor angiogenesis at different levels. We report on a novel combinatorial metronomic antiangiogenic approach. The study is a retrospective observational study of 29 consecutive patients with first or multiple recurrences prospectively treated according to the MEMMAT strategy ('MEMMAT-like') before the formal protocol (MEMMAT; ClinicalTrials.gov Identifier: NCT01356290) started. The study period was 11/2006 to 06/2016. Treatment consisted of daily oral thalidomide, fenofibrate, celecoxib, and alternating 21-day cycles of low-dose oral etoposide and cyclophosphamide supplemented by IV bevacizumab and intraventricular therapy consisting of alternating etoposide and liposomal cytarabine. Median overall survival (OS) after recurrence for the whole group was 29.5 months, OS was 48.3 ± 9.3% at three years and 34.5 ± 8.8% at five years, and progression-free survival was 42.0 ± 9.5% at three years and 29.4 ± 9% at five years. As of 07/2022, 9/29 patients are alive 86 to 164 months after the recurrence that prompted the 'MEMMAT-like' therapy. Treatment was primarily out-patient and generally well-tolerated. Toxicities did occur but were manageable. In conclusion, antiangiogenic therapy according to the MEMMAT strategy increased median OS of patients with recurrent MB and may lead to long-term survival. Adherence to the protocol, including intraventricular therapy, appears important.
000182306 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000182306 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000182306 650_7 $$2Other$$aMEMMAT
000182306 650_7 $$2Other$$aantiangiogenic therapy
000182306 650_7 $$2Other$$abevacizumab
000182306 650_7 $$2Other$$aintraventricular therapy
000182306 650_7 $$2Other$$alow-dose oral therapy
000182306 650_7 $$2Other$$amedulloblastoma recurrence
000182306 650_7 $$2Other$$ametronomic therapy
000182306 7001_ $$00000-0002-6841-0749$$aMayr, Lisa$$b1
000182306 7001_ $$aStepien, Natalia$$b2
000182306 7001_ $$aGojo, Johannes$$b3
000182306 7001_ $$aAliotti Lippolis, Maria$$b4
000182306 7001_ $$aAzizi, Amedeo A$$b5
000182306 7001_ $$aChocholous, Monika$$b6
000182306 7001_ $$00000-0002-0894-4167$$aBaumgartner, Alicia$$b7
000182306 7001_ $$aHedrich, Cora S$$b8
000182306 7001_ $$aHolm, Stefan$$b9
000182306 7001_ $$aSehested, Astrid$$b10
000182306 7001_ $$00000-0002-7088-2614$$aLeblond, Pierre$$b11
000182306 7001_ $$aDieckmann, Karin$$b12
000182306 7001_ $$00000-0003-1016-0545$$aHaberler, Christine$$b13
000182306 7001_ $$00000-0001-8112-2795$$aCzech, Thomas$$b14
000182306 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b15$$udkfz
000182306 7001_ $$00000-0002-5736-8231$$aPeyrl, Andreas$$b16
000182306 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers14205128$$gVol. 14, no. 20, p. 5128 -$$n20$$p5128$$tCancers$$v14$$x2072-6694$$y2022
000182306 909CO $$ooai:inrepo02.dkfz.de:182306$$pVDB
000182306 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000182306 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000182306 9141_ $$y2022
000182306 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000182306 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000182306 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-05-04
000182306 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000182306 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000182306 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000182306 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2021$$d2022-11-30
000182306 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-30
000182306 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-30
000182306 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-01-24T07:56:58Z
000182306 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-01-24T07:56:58Z
000182306 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-01-24T07:56:58Z
000182306 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-30
000182306 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-30
000182306 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-30
000182306 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-30
000182306 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-30
000182306 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2021$$d2022-11-30
000182306 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000182306 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000182306 980__ $$ajournal
000182306 980__ $$aVDB
000182306 980__ $$aI:(DE-He78)B062-20160331
000182306 980__ $$aI:(DE-He78)HD01-20160331
000182306 980__ $$aUNRESTRICTED